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Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)–
positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved
overall outcomes; however, a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was dem-
onstrated to reduce the risk of relapse in a large retrospective study and, therefore, should be considered a valuable option. This con-
sensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation,
presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the
choice of TKI, treatment timing, and dosage. It is hoped that these recommendations will become the state of art in this field and,
more importantly, lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;000:000–000. VC 2016 American Cancer
Society.
KEYWORDS: allogeneic hematopoietic stem cell transplantation, dasatinib, imatinib, maintenance therapy, nilotinib, Philadelphia chro-
mosome–positive acute lymphoblastic leukemia, recommendations, tyrosine kinase inhibitors.
INTRODUCTION
The presence of the Philadelphia chromosome (Ph) in acute lymphoblastic leukemia (ALL) has been recognized as a quite
adverse independent prognostic factor for more than 30 years.1 This chromosomal abnormality is one of the most com-
mon in adult patients with ALL, and the rate increases with age. Translocation (9;22) or the BCR-ABL fusion gene is
detected in approximately 5% to 15% of adolescents, in 25% to 30% of patients aged 25 to 35 years, and in more than
35% to 40% of patients older than 35 years.2,3 Historically, treatment results for Ph-positive ALL were very poor, and a
patient’s prognosis was dismal.4,5 Although complete remission (CR) was obtained in 60% to 90% of patients after first-
line therapy, the relapse rate was very high, and the probability of long-term survival did not exceed 10% in patients
treated with standard chemotherapy and 30% to 35% in those undergoing allogeneic hematopoietic stem cell transplanta-
tion (alloHSCT).4,5 Furthermore, a significant proportion of patients could not proceed to alloHSCT because of early
relapse.
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The introduction of the BCR-ABL–directed tyrosine
kinase inhibitors (TKIs) to the front-line therapy for Ph-
positive ALL has improved CR rates, the quality of
responses, and the duration of remission.6,7 The combina-
tion of imatinib or second-generation TKIs (eg, dasatinib
and nilotinib) with either corticosteroids or multi-agent
chemotherapy results in 90% to 100% CR rates along
with deep molecular response rates of 38% to 72%.8-12
However, without alloHSCT, most patients ultimately
relapse, so transplantation from either related or unrelated
donors remains a standard of care and should be consid-
ered for all eligible patients.12 Moreover, with upfront use
of TKIs, up to 77% of transplant-eligible patients are able
to proceed to alloHSCT during their first complete remis-
sion (CR1).8 Treatment strategies that are based on TKIs
combined with chemotherapy or corticosteroids for front-
line treatment followed by alloHSCT during CR1 facilitate
long-term survival in 30% to 65% of patients.10-12 Accord-
ing to retrospective analyses, the results of alloHSCT with
myeloablative and reduced-intensity conditioning for Ph-
positive ALL are comparable in terms of overall survival
(OS).13,14 The availability of TKIs also enables bridging a
Ph-positive ALL patient without a related donor or with a
major infection to alloHSCT and allows sufficient time for
the allocation of an unrelated donor or recovery from an
invasive fungal infection, respectively.15,16
Although the use of TKIs is associated with better dis-
ease control before transplantation, relapses after alloHSCT
remain a major reason for treatment failure. Relapse rates
are particularly high among patients in whom BCR-ABL
transcripts are detectable after alloHSCT.17 Strategies to
reduce the incidence of relapse include posttransplant main-
tenance with the use of TKIs.10,18-21 Their role, however,
remains a subject of uncertainty because of the paucity of
prospective studies and the conflicting results of retrospec-
tive analyses. Furthermore, there are no commonly accepted
standards with respect to the choice of TKI, dosage, time of
initiation, treatment duration, or potential of a combina-
tion with donor lymphocyte infusions (DLIs).
In this article, we summarize the clinical experience
with the use of TKIs after alloHSCT and present the posi-
tion statement elaborated by the experts of the Acute Leu-
kemia Working Party of the European Society for Blood
andMarrow Transplantation (EBMT).
OVERVIEW OF STUDIES ON TKI
MAINTENANCE AFTER ALLOHSCT
Retrospective Studies
Several retrospective, comparative analyses were per-
formed with the aim of evaluating the impact of the use of
TKIs after alloHSCT on outcomes. Most of them
included rather small groups of patients.
Nishiwaki et al22 performed a multicenter study that
included 34 patients; 7 of these patients were treated with
imatinib after alloHSCT either prophylactically or pre-
emptively (ie, in the case of a positive minimal residual
disease [MRD] status).22 The posttransplant use of imati-
nib was associated with a significantly improved probabil-
ity of OS (67% vs 30% at 2 years; P 5 .03). The
probabilities of leukemia-free survival (LFS) were 56%
and 30%, respectively (P5 .29).
In the study by Kebriaei et al,23 which involved 102
adults and 11 children with Ph-positive ALL who were
treated with alloHSCT during CR1 (n5 71), the second
complete remission (CR2; n5 11), or active disease (n5
31), 32 individuals received TKI maintenance with either
imatinib (n 5 31) or dasatinib (n 5 1) for a median of
10.6 months. AlloHSCT procedures included transplants
from sibling and unrelated donors and the use of cord
blood as a source of stem cells. Seven patients stopped
TKIs because of disease recurrence, whereas 8 patients
stopped because of excess toxicity (fluid retention, n5 2;
nausea, n5 2; and cytopenia, n5 4). In a univariate anal-
ysis, the use of a TKI after transplantation was not associ-
ated with a better outcome, although in a subgroup of
patients treated during CR1, there was a tendency toward
improved OS (hazard ratio [HR], 0.4; 95% confidence
interval [CI], 0.1-1.3; P5 .1). On the other hand, among
patients with detectable MRD before alloHSCT, the rate
of progression was 31%, regardless of the posttransplant
use of TKIs.
The largest analysis, including 473 alloHSCT recip-
ients, has been recently published on behalf of the EBMT
Acute Leukemia Working Party.13 One hundred fifty-
seven adult patients received TKIs, most frequently imati-
nib (n 5 124) and dasatinib (n 5 26), for primary pro-
phylaxis against relapse. The study population was
restricted to patients in CR1 who had been treated with
alloHSCT involving either a matched sibling or an unre-
lated donor. The posttransplant use of TKIs was included
in a multivariate analysis as a time-dependent covariate. It
was associated with improved OS (HR, 0.44; 95% CI,
0.26-0.74; P5 .002) and LFS (HR, 0.42; 95% CI, 0.23-
0.76; P 5 .004) as well as a reduced risk of relapse (HR,
0.4; 95% CI, 0.21-0.76; P5 .01) and a tendency toward
a reduced risk of nonrelapse mortality (HR, 0.46; 95%
CI, 0.2-1.1; P 5 .01). Furthermore, TKI maintenance
was significantly associated with a lower cumulative inci-
dence of grade 2 to 4 acute graft-versus-host disease
(GVHD; HR, 0.21; 95% CI, 0.05-0.85; P 5 .03).
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Although the study had some important limitations asso-
ciated with its retrospective nature, including a lack of
data on the dose and timing of TKIs as well as the MRD
status, the analyzed population was relatively homogene-
ous. Therefore, the obtained results provide a strong ra-
tionale for the use of TKIs as maintenance after
alloHSCT for patients with Ph-positive ALL in CR1.
Prospective Studies
The use of TKIs after alloHSCT was a subject of 6 pro-
spective studies, including 1 randomized trial (Table 1).
Five trials examined imatinib and 1 study examined nilo-
tinib as posttransplant TKIs. Two single-arm studies
recruited recipients of both alloHSCT and autologous he-
matopoietic stem cell transplantation (autoHSCT). Two
studies included mixed populations of patients with ALL
and chronic myeloid leukemia (CML).
In the study by Wassmann et al,17 imatinib was
administered at an initial dose of 400 mg/d to patients
with detectable MRD after either alloHSCT (n 5 25) or
autoHSCT (n 5 2). Notably, 22% of the patients were
beyond CR1 at the time of hematopoietic stem cell trans-
plantation (HSCT). In 14 patients (52%), the BCR-ABL
transcript became undetectable after a median of 1.5
months. None of the 5 patients who had received trans-
plants during their first or second relapse or had refractory
disease achieved molecular CR, whereas 13 of 21 patients
(62%) who underwent transplantation during CR1 did.
Patients achieving molecular remission remained relapse-
free during imatinib administration. Three of them
relapsed after the treatment discontinuation. Among the
patients who failed to achieveMRD negativity, the relapse
rate was 92%. The LFS rate at 1 year was 91% for patients
with early MRD negativity and 9% for those who
remained MRD-positive. The authors concluded that
continued detection of BCR-ABL transcripts after 2 to 3
months on imatinib identifies patients who will ultimately
experience relapse and for whom additional or alternative
antileukemic treatment should be initiated.
Carpenter et al18 administered imatinib after
alloHSCT prophylactically, regardless of the MRD status.
The study population included 22 patients, 11 with ALL
and 11 with CML. Among patients with Ph-positive
ALL, with a median follow-up of 1.3 years, the relapse
rate was 9%, whereas the probability of OS was 80%. The
posttransplant use of imatinib was found to be feasible.
The Spanish group Programa Espa~nol de Trata-
mientos en Hematologıa (PETHEMA) conducted a study
on newly diagnosed Ph-positive ALL. Among the 30
patients, 21 proceeded to either alloHSCT or
autoHSCT.10 Finally, 8 alloHSCT recipients and 4
autoHSCT recipients were treated with imatinib mainte-
nance. The reasons for not initiating imatinib treatment
were mainly transplant-related complications. Further-
more, treatment interruptions were reported in 10 cases,
although only in 2 patients were they associated with
drug-related toxicities (cytopenia and gastrointestinal
complications). The long-term outcomes of patients
treated with posttransplant imatinib were not reported.
In a Chinese study including both adults and chil-
dren, imatinib maintenance was scheduled for 3 to 12
months after alloHSCT until MRD negativity was
TABLE 1. Prospective Studies of the Use of TKIs After Allogeneic Hematopoietic Stem Cell Transplantation
Study
Type











Wassmann 200517 Imatinib Preemptive 27 (including
2 autoHSCTs)
Not reported Not reported 55% (8 mo) Not reported Not reported
Carpenter 200718 Imatinib Prophylactic 22 (ALL 1CML) 11 (ALL) 9%
(ALL 1 CML)
13% (ALL) Not reported 80% (1.3 y, ALL)
Ribera 201010 Imatinib Prophylactic 13 (including
4 autoHSCTs)
9 20% 33% Not reported Not reported
Chen 201219 Imatinib Prophylactic 62 3 16% 10% (5 y) 82% (5 y) 87% (5 y)




Not reported Not reported Not reported
Randomized
Pfeifer 201320 Imatinib Prophylactic
Preemptive
26 7 67%b 8% (30 mo) 69% (5 y, 77%
29 4 71%b 17% (32 mo) all patients) (5 y, all patients)
Abbreviations: ALL, acute lymphoblastic leukemia; autoHSCT, autologous hematopoietic stem cell transplantation; CML, chronic myeloid leukemia; LFS,
leukemia-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor.
a For single-arm studies, only patients effectively treated with TKIs were considered.
b Treatment discontinuation for any reason.
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confirmed by 3 consecutive tests or was sustained for at
least 3 months.19 The initial dose for adults was 400 mg/
d. Imatinib was administered to 62 of 82 enrolled
patients. Reasons for not starting TKI maintenance were
pancytopenia, infections, gut GVHD, and personal deci-
sions. Imatinib therapy was initiated at a median time of
70 days after alloHSCT, and the median treatment dura-
tion was 90 days. Although 71% of the patients experi-
enced possible drug-related complications, they were the
cause of treatment termination (cytopenias, edema, and
nausea/emesis) in only 10 cases (16%). The probabilities
of relapse, LFS, and OS at 5 years for patients receiving
imatinib maintenance were 10%, 81.5%, and 87%,
respectively. The results of the study confirmed the feasi-
bility and suggested high efficacy of imatinib prophylaxis
after alloHSCT.
The only randomized trial referring to the posttrans-
plant use of imatinib was performed by a German group
German multicenter study group for adult acute lympho-
blastic leukemia (GMALL).20 Their aim was to compare
2 strategies: prophylactic and MRD-triggered therapy. In
the prophylactic treatment arm (n5 26), all patients who
underwent engraftment, had no uncontrolled GVHD or
infections, and had adequate organ function were
intended to receive imatinib. In the preemptive treatment
arm (n5 29), the drug was initiated only after the detec-
tion of MRD by quantitative real-time polymerase chain
reaction (PCR); this was confirmed by nested PCR. The
target dose of imatinib was 600 mg/d. The median times
to treatment initiation were 48 and 70 days after
alloHSCT, respectively, and the median treatment dura-
tions were 201 and 127 days, respectively. Notably, a ma-
jority of patients (67% and 71%) in both groups
discontinued treatment prematurely. Moreover, only
22% received the intended imatinib dose (600 mg/d),
whereas the majority received 400 mg/d. Although there
was a tendency toward a longer duration of molecular
remission in the prophylactic treatment arm, the proba-
bilities of LFS and event-free survival did not differ signif-
icantly, and the OS rates were essentially superimposable
(80% vs 75% at 5 years; P5 .84). The authors concluded
that despite unexpectedly low compliance, the use of ei-
ther prophylactic or preemptive treatment with imatinib
is associated with a low risk of hematologic relapse and
contributes to excellent long-term outcomes. It was
hypothesized that even short-term treatment may be suffi-
cient to prevent hematologic relapse. The results of the
GMALL study appear superior to those of other prospec-
tive trials conducted in the era of TKIs without posttrans-
plant maintenance. In a recently published study by a
French group,12 the reported LFS rates after alloHSCT
with human leukocyte antigen–identical siblings and
unrelated donors were 42% and 57%, respectively, at 5
years.
The only prospective study of the use of the second-
generation TKI nilotinib was performed by Shimoni
et al.21 Among 22 alloHSCT recipients with CML (n 5
15) or Ph-positive ALL (n 5 7), nilotinib maintenance
was introduced for 16 individuals. The treatment was ini-
tiated at a median of 38 days after alloHSCT. The maxi-
mum tolerated dose was 200 mg every 12 hours, although
there was an intention to escalate the dose to 400mg every
12 hours. Ten episodes of grade 3 or 4 adverse events were
reported (liver toxicities, elevated lipase/amylase levels,
neutropenia, allergy, skin reaction, and stroke), and they
led to treatment discontinuation in 6 cases. Eleven
patients achieved or maintained molecular remission, and
only 1 of these patients relapsed. Outcomes specific for
patients with Ph-positive ALL were not reported.
CHOICE OF TKI FOR POSTTRANSPLANT
MAINTENANCE
Almost all prospective and retrospective studies of post-
transplant TKI maintenance have examined the use of
imatinib and indicated its efficacy in preventing relapse
and eradicating Ph-positive leukemic cells. Its safety pro-
file has been relatively well defined. Treatment with nilo-
tinib has been tested in a single prospective phase 1/2
trial,21 whereas therapy with dasatinib has been the sub-
ject of case reports and small retrospective cohorts, the
largest including 8 alloHSCT recipients.24-28 Reports on
dasatinib indicate the possibility of eradicatingMRD after
imatinib failure along with acceptable tolerance of the
treatment. It should be mentioned, however, that 1 case
series report showed a high incidence of extramedullary
relapse, which was detected in 3 of 6 patients on post-
transplant dasatinib therapy.28 The use of third-
generation TKIs such as ponatinib as maintenance after
alloHSCT has not been reported so far. Altogether, on the
basis of available data, imatinib should be considered the
first-choice TKI for posttransplant maintenance. How-
ever, there are several clinical scenarios in which an alter-
native TKI may be considered from the outset after
alloHSCT. Similarly, the reappearance or persistence of
BCR-ABL transcripts during imatinib treatment or its
poor tolerability may mandate a change in TKI.
The results of the randomized GMALL study of
imatinib given prophylactically or as MRD-triggered
therapy demonstrated a high probability of maintaining
hematologic remission in the whole study group.20
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However, a detailed analysis revealed that the early reap-
pearance of the BCR-ABL transcript (ie, within the 3
months after alloHSCT) and/or its reappearance at a high
level (>1024) was associated with a high risk of relapse
and a low probability of LFS despite imatinib administra-
tion. The authors suggested that these adverse factors
could allow the identification of a population of patients
for whom second-generation TKIs may be beneficial.
Another group of patients who should be considered
for the use of second-generation TKIs in posttransplant
maintenance therapy are those who have experienced re-
sistance to pretransplant treatment with imatinib. Sover-
ini et al29 demonstrated that approximately 70% of
patients with resistance to imatinib are characterized by
point mutations within the ABL kinase domain, with
T315I, E255K, and Y253H being the most common
ones. Moreover, there are data indicating that Ph-positive
ALL patients with detectable BCR-ABL transcripts and
kinase domain mutations before alloHSCT relapse after
transplantation with the same mutation. Egan et al30 ana-
lyzed ABL kinase domain mutations in patients with
CML and Ph-positive ALL who had detectable BCR-ABL
transcripts before alloHSCT. Pretransplant ABL kinase
domain mutations were found in 14 patients, including 4
patients with Ph-positive ALL. Seven of those patients
had relapsed or continued to have refractory disease after
alloHSCT. These data suggest that the choice of TKI for
posttransplant maintenance therapy in patients with re-
sistance to imatinib or with detectable BCR-ABL tran-
scripts before transplantation should be based on a
mutation analysis taking into consideration resistance
profiles of TKIs. Unfortunately, an analysis of the muta-
tion status for patients with low levels of MRD is difficult
because of the limited sensitivity of the methods. The
most commonly used bidirectional Sanger sequencing of
the entire BCR-ABL1 tyrosine kinase domain amplified
by PCR does not reveal the presence of mutant subclones
representing less than 10% to 20% of the Ph-positive cell
pool.31 Other techniques such as long-range, next-genera-
tion sequencing are more sensitive; however, so far they
are not widely available.32
Prior leukemic involvement of the central nervous
system (CNS) is another specific clinical situation that
should be taken into consideration when a TKI is being
chosen. Imatinib poorly penetrates the CNS and does not
reach adequate concentration for kinase inhibition.33
Moreover, isolated CNS relapse occurs in up to 20% of
patients with Ph-positive ALL during imatinib monother-
apy.34,35 In contrast, dasatinib penetration into the CNS
was demonstrated in a cerebrospinal fluid pharmacoki-
netic study performed by Porkka et al.36 Its clinical activ-
ity in the CNS has been documented in several case
reports.37-39 On the basis of these data, dasatinib mainte-
nance therapy after alloHSCT should be considered a
rational strategy for patients with a history of CNS
involvement.
The tolerability of TKIs after alloHSCT is another
important issue that may affect the choice of drug. Imati-
nib therapy in the early period after alloHSCT is associ-
ated with a high incidence of gastrointestinal intolerance
and hematological side effects leading to dose reductions
or the withholding of therapy.10,18,20 During dasatinib
maintenance therapy, grade 2 hematologic toxicity, diar-
rhea, and pleural effusion requiring dose reductions were
reported.25 Nilotinib given at the standard dose was not
well tolerated because of gastrointestinal and liver side
effects; however, grade 2 to 4 hematologic toxicities were
infrequent.21 In conclusion, the available data are insuffi-
cient to determine which TKI is better tolerated in the
early period after alloHSCT. The decision has to be made
individually and be guided by comorbidities and post-
transplant complications.
TKI TIMING AND DOSAGE AFTER
ALLOHSCT
According to the GMALL study, prophylactic use and
preemptive use of imatinib are equally effective in pre-
venting relapse after alloHSCT.20 A preemptive strategy
should be applied only if adequate monitoring of BCR-
ABL transcripts is available with the use of real-time quan-
titative PCR (confirmed by nested PCR).40 The first eval-
uation should be performed after engraftment, preferably
within the month after alloHSCT. In the GMALL study,
22% of the patients were already PCR-positive within the
3 months after stem cell transplantation (median, 34 days;
range, 23-81 days), and the median time to the first detec-
tion of BCR-ABL1 transcripts among all patients who
became MRD-positive was 4.1 months (range, 0.9-26.5
months).20 Therefore, a high monitoring frequency, as in
this study, with a bone marrow evaluation every 6 weeks
and an assessment in peripheral blood every 3 weeks
appears prudent.
With a preemptive strategy, a significant proportion
of patients may avoid potentially toxic treatment with
TKIs. Patients who cannot be rigorously monitored for
the MRD status should be treated prophylactically.
According to the design of prospective studies, treatment
should be started as soon as possible after engraftment in
the absence of uncontrolled GVHD or infections.
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The optimal treatment duration has not been
defined so far. According to the study by Chen et al,19 the
treatment should be continued until MRD negativity is
confirmed by 3 consecutive tests or sustained for at least 3
months. Relapses occurring relatively late after imatinib
discontinuation were observed in the study by Wassmann
et al,17 and this suggests that too early discontinuation of
TKIs may carry risks for some patients and should be bal-
anced against tolerability. In the GMALL study, imatinib
administration was scheduled for 1 year of continuous
PCR negativity, with a single positive result resetting the
treatment period.20 In view of the poor compliance in this
study with respect to prolonged treatment, the potential
advantages of better disease control may in clinical prac-
tice be offset by drug-related toxicities. At present, there is
no conclusive evidence showing that these considerations
do not apply to second-generation TKIs.
In terms of treatment efficacy, the optimal dose of
imatinib for patients with Ph-positive ALL is 600 mg/d;
however, the vast majority of patients do not tolerate it af-
ter alloHSCT. It appears reasonable to start with the dose
of 400 mg/d and to try to increase it in cases of good toler-
ance. On the other hand, the risk of the occurrence of
severe adverse events is high, and even 400 mg/d may be
intolerable. Therefore, decisions on the dose of imatinib
should be made individually.
According to the results of the prospective study,
the maximum tolerated dose of nilotinib is 200 mg every
12 hours.21 Results of retrospective case series studies
suggest that the appropriate dose of dasatinib after
alloHSCT is 100 mg/d, although in the cohort reported
by Caocci et al,25 in 5 of 8 patients, the dose was reduced
to 50 mg/d.28
SUMMARY OF THE POSITION STATEMENT
There is a lack of grade 1 evidence for the use of posttrans-
plant TKIs, and all the subsequent recommendations are
based on a consensus of experts:
1. All patients with Ph-positive ALL are candidates for
the posttransplant use of TKIs to reduce the risk of
relapse.
2. Patients should be evaluated for the presence of BCR-
ABL transcripts and for whether they are positive for
the presence of ABL kinase domain mutations before
alloHSCT and after engraftment (Fig. 1).
3. MRD monitoring should start 4 weeks after
alloHSCT. During the first year of treatment, the anal-
ysis should be continued every 6 to 8 weeks in bone
marrow and every 3 to 4 weeks in peripheral blood.
The detection of MRD should prompt rapid confirma-
tory testing.
4. Patients with undetectable MRD after alloHSCT may
be treated prophylactically or, alternatively, may be
monitored and administered a TKI only after the
detection of MRD (preemptive strategy).
5. Patients with detectable MRD after alloHSCT should
be started on TKI treatment as soon as possible.
6. Imatinib at an initial dose of 400 mg/d is the first-
choice TKI. Patients with early molecular recurrence
(ie, within the 3 months after HSCT) or BCR-ABL
transcripts at a level higher than 104 at any time after
HSCT appear to derive little benefit from intervention
with imatinib and should be started on a second-
generation TKI instead (nilotinib at 200 mg every 12
hours or dasatinib at 50-100 mg/d). It should be recog-
nized that nilotinib is not licensed for use in patients
with Ph-positive ALL. Second-generation TKIs should
be used in cases of resistance to imatinib or if ABL ki-
nase domain mutations are present either before
alloHSCT or after alloHSCT. In addition, switching
to a second-generation TKI is recommended if BCR-
ABL transcript levels remain detectable after 6 to 8
weeks of posttransplant imatinib.
7. Patients with a history of CNS involvement should be
treated with dasatinib.
8. For patients undergoing transplantation during CR1,
TKI treatment should be given for 12 months of con-
tinuous MRD negativity. For patients undergoing
HSCT during CR2 or a later remission, treatment
should be given indefinitely unless this is precluded by
poor tolerability or safety concerns. Individual adjust-
ments may be needed in cases of severe toxicity.
9. Both hematologic and nonhematologic adverse events
should be monitored periodically according to the TKI
toxicity profile (Table 2).
FUTURE DIRECTIONS
The issue of TKI treatment after alloHSCT remains a rel-
atively poorly explored area of investigation with many
open questions requiring further research. Both prospec-
tive and retrospective studies included mostly patients
undergoing allografting during CR1 and receiving mye-
loablative alloHSCT. It is plausible but as yet untested
that the optimal posttransplant choice of TKI and treat-
ment schedule should differ according to the intensity of
the preparative regimens. As demonstrated by Bachanova
et al,13 the risk of relapse is higher after reduced-intensity
conditioning versus myeloablative conditioning,
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especially if the MRD status is positive before alloHSCT.
In such a situation, a significant proportion of relapses
occur later than 1 year after transplantation, and this sug-
gests the need to administer a more potent TKI for more
prolonged TKI maintenance. For patients on a TKI in
whom BCR-ABL1 transcripts remain detectable, a DLI
could be an additional intervention to reduce the risk of
relapse. Although a synergistic effect of DLIs and imatinib
treatment has been reported in a setting of CML, such
data for Ph-positive ALL are not yet available.41 In view of
the delayed onset of clinical activity and the uncertain effi-
cacy of DLIs, switching to a more potent TKI should be
the preferred option even when DLIs are being consid-
ered. The third-generation TKI ponatinib has been used
in the posttransplant setting in the 2 initial phase 1 and 2
studies and a recent case report by Hirschbuehl et al.42-44
Although only a minority of these patients had Ph-
positive ALL, the studies demonstrated the feasibility and
efficacy of ponatinib in the posttransplant setting but also
indicated the need to be cognizant of adverse events.
Additional novel options attractive for clinical trials
because of their favorable risk-benefit ratio in the setting
of relapsed B-cell precursor ALL include monoclonal
antibodies such as inotuzumab ozogamicin and the bis-
pecific T-cell engager antibody blinatumomab, although
data on Ph-positive ALL are limited, and only a few of
these patients have been treated in the setting of
MRD.45,46
Rigorous monitoring of MRD allows the identifica-
tion of the patients who will benefit most from TKI treat-
ment after alloHSCT. However, the sensitivity of the
methods used for MRD detection varies, and in contrast
to p210 in the case of CML, the quantification of p190,
typical for ALL, by real-time quantitative PCR is still
insufficiently standardized. A new approach based on
microfluidic digital PCR with TaqMan chemistry and
allowing the detection of rare copies of BCR-ABL1 in Ph-
positive ALL has been proposed.47 Its application might
allow more accurate discrimination between patients in
need and those not requiring TKI maintenance.
Figure 1. Recommendations for the use of TKIs according to the pre- and posttransplant MRD status. The MRD status should be
checked before alloHSCT and monitored after transplantation; the posttransplant monitoring should start early after engraftment.
In the case of MRD positivity, as defined by detectable BCR-ABL transcripts, the status of BCR-ABL domain mutations should be
checked if possible. Imatinib is the first-choice TKI for posttransplant maintenance. Second- or third-generation TKIs should be
used in case of kinase domain mutations conferring resistance to imatinib. Second-generation TKIs should also be considered if
there is early reoccurrence of MRD (within 3 months) or if BCR-ABL transcripts are detected at a level higher than 104. Detailed
recommendations are described in the text. AlloHSCT indicates allogeneic hematopoietic stem cell transplantation; HSCT, hema-
topoietic stem cell transplantation; MRD, minimal residual disease; TKI, tyrosine kinase inhibitor.
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The issue of poor TKI tolerance after alloHSCT
remains a major concern. It can be speculated that the
intermittent administration or alternating use of different
TKIs might reduce the toxicity of the treatment. Such
approaches, however, require verification in prospective
trials. On the other hand, imatinib is known to inhibit
pathways related to transforming growth factor b and
platelet-derived growth factor receptor, which play a role
in the pathogenesis of chronic GVHD.48,49 Imatinib
treatment was found to be effective as a salvage treatment
for steroid-refractory chronic GVHD.50,51 In a single ret-
rospective analysis of patients with Ph-positive ALL, the
use of posttransplant imatinib maintenance was associated
with reductions in both the incidence and severity of this
complication.52 Significant differences were demon-
strated with respect to the gut and oral mucosa as target
organs. Therefore, it is worth examining whether treat-
ment with TKIs after alloHSCTmay overall contribute to
an improved quality of life.
As suggested by the results of 2 prospective studies,
autologous HSCT may be a valuable option for patients
lacking a donor.12,53 In a retrospective analysis by the
TABLE 2. Monitoring of Hematologic and Nonhematologic Adverse Events During TKI Maintenance Therapy
After Allogeneic Haematopoietic Stem Cell Transplantation
TKI TKI-Associated Hematologic Adverse Events Monitoring
All TKIs Cytopenias Routine, frequent complete blood counts:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
TKI TKI-Associated Nonhematologic Adverse Events Monitoring
Imatinib Abdominal pain, nausea, diarrhea, edema, muscle cramps,
musculoskeletal pain, rash, fatigue, and headache
Physical examination:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Hypophosphatemia and liver toxicity Monitoring of electrolyte, phosphate, transaminase, and bilirubin
levels:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Nilotinib Gastrointestinal disturbances, rash, and headache Physical examination:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Elevation of bilirubin, transaminases, lipase, and amylase; elec-
trolyte abnormalities; and hyperglycemia
Monitoring of electrolyte, glucose, lipase, amylase, transami-
nase, and bilirubin levels:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
QTc interval prolongation Electrocardiogram at baseline, 7 days after initiation, and peri-
odically thereafter
Dasatinib Pleural effusion, dyspnea, gastrointestinal disturbances, rash,
headache, and fatigue
Physical examination:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Hypocalcemia and elevation of transaminases and bilirubin Monitoring of electrolyte, transaminase, and bilirubin levels:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
QTc interval prolongation Electrocardiogram at baseline and periodically thereafter for
patients who are at risk for QTc prolongation (patients who
are taking anti-arrhythmic medicines, patients with congenital
long QT syndrome, and patients with hypokalemia or
hypomagnesemia)
Ponatinib Vascular occlusion, hypertension, congestive heart failure, and
hemorrhage
Cardiovascular assessment at baseline
Physical examination:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Pancreatitis Monitoring of serum lipase:
 Every 2 wk for first 2 mo
 Periodically thereafter
Elevation of bilirubin, transaminases, and alkaline phosphatase Monitoring of bilirubin, transaminase, and alkaline phosphatase
levels:
 Every 2–4 wk during initial treatment
 Every 6–8 wk thereafter
Abbreviation: TKI, tyrosine kinase inhibitor.
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EBMT, the results of autologous HSCT improved mark-
edly in the era of TKIs with a 3-year LFS rate of 60%.
Among 32 patients pretreated with TKIs, 29 also received
posttransplant maintenance with either imatinib or dasa-
tinib. This promising strategy requires further prospective
evaluation.54
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